Windlas Biotech appoints Komal Gupta as CEO
The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO
The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
A pharma industry veteran with over three decades of experience in domestic as well as international markets
On the day dedicated to the battle against the deadly disease – took to reaching the public of Pune to understand that cancer can be prevented and even reversed with the help of adequate testing
He is a Chartered Accountant with more than 19 years of extensive experience
During the quarter, foreign exchange fluctuations had an impact of Rs. 4.56 crore Q3 FY23 Profit After Tax after considering exchange rate fluctuations stood at Rs. 8.2 crore
It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis
Subscribe To Our Newsletter & Stay Updated